Antinociception by Spinal and Systemic Oxycodone: Why Does the Route Make a Difference?
Open Access
- 1 October 2006
- journal article
- laboratory investigations
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 105 (4), 801-812
- https://doi.org/10.1097/00000542-200610000-00027
Abstract
Background The pharmacology of oxycodone is poorly understood despite its growing clinical use. The discrepancy between its good clinical effectiveness after systemic administration and the loss of potency after spinal administration led the authors to study the pharmacodynamic effects of oxycodone and its metabolites using in vivo and in vitro models in rats. Methods Male Sprague-Dawley rats were used in hot-plate, tail-flick, and paw-pressure tests to study the antinociceptive properties of morphine, oxycodone, and its metabolites oxymorphone and noroxycodone. Mu-opioid receptor agonist-stimulated GTPgamma[S] autoradiography was used to study G-protein activation induced by morphine, oxycodone, and oxymorphone in the rat brain and spinal cord. Spontaneous locomotor activity was measured to assess possible sedation or motor dysfunction. Naloxone and the selective kappa-opioid receptor antagonist nor-binaltorphimine were used to study the opioid receptor selectivity of the drugs. Results Oxycodone showed lower efficacy and potency to stimulate GTPgamma[S] binding in the spinal cord and periaqueductal gray compared with morphine and oxymorphone. This could relate to the fact that oxycodone produced only weak naloxone-reversible antinociception after intrathecal administration. It also suggests that the metabolites may have a role in oxycodone-induced analgesia in rats. Intrathecal oxymorphone produced strong long-lasting antinociception, whereas noroxycodone produced antinociception with very high doses only. Subcutaneous administration of oxycodone and oxymorphone produced thermal and mechanical antinociception that was reversed by naloxone but not by nor-binaltorphimine. Oxymorphone was more potent than oxycodone, particularly in the hot-plate and paw-pressure tests. Conclusions The low intrathecal potency of oxycodone in rats seems be related to its low efficacy and potency to stimulate mu-opioid receptor activation in the spinal cord.Keywords
This publication has 43 references indexed in Scilit:
- Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinansLife Sciences, 1999
- The orphan opioid receptor and its endogenous ligand — nociceptin/orphanin FQTrends in Pharmacological Sciences, 1997
- Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptorNature, 1995
- Liposolubility and Protein Binding of Oxycodone in VitroBasic & Clinical Pharmacology & Toxicology, 1994
- Molecular cloning of a rat κ opioid receptor reveals sequence similarities to the μ and δ opioid receptorsBiochemical Journal, 1993
- Cloning and functional comparison of kappa and delta opioid receptors from mouse brain.Proceedings of the National Academy of Sciences, 1993
- Cloning of a Delta Opioid Receptor by Functional ExpressionScience, 1992
- The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.Proceedings of the National Academy of Sciences, 1992
- The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.British Journal of Clinical Pharmacology, 1992
- Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronideClinical Pharmacology & Therapeutics, 1990